Revolutionary Findings on IASO Bio's CAR-T Therapy for Multiple Sclerosis Unveiled Recent research by IASO Biotherapeutics reveals groundbreaking results on their CAR-T therapy for treating Multiple Sclerosis, showcasing safety and efficacy.

Revolutionary Findings on IASO Bio's CAR-T Therapy for Multiple Sclerosis Unveiled #China #Shanghai #IASO_Biotherapeutics #Equecabtagene_Autoleucel #BCMA_CAR-T

IASO Bio Secures Significant Orphan Drug Designation for Novel CAR-T Therapy in South Korea IASO Biotherapeutics receives Orphan Drug Designation for Equecabtagene Autoleucel from South Korea, paving the way for innovative treatments in multiple myeloma.

IASO Bio Secures Significant Orphan Drug Designation for Novel CAR-T Therapy in South Korea #South_Korea #Seoul #CAR-T_therapy #IASO_Biotherapeutics #Equecabtagene_Autoleucel